Latest From Selvita SA
Asian oncology venture gains worldwide rights to novel molecule series from Inflection, giving a leg up to its global ambitions.
Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.
Appointments: Stada, Astellas, Novo Nordisk, Boehringer Ingelheim, Dova, Selvita, Orchard, MannKind, Cancer Genetics
The latest biopharma industry appointments include CEOs for Stada and Astellas, a finance chief for Novo Nordisk and a new president for Boehringer Ingelheim in the US, while Orchard Therapeutics has made a key addition to its scientific advisory board.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Neurology, Nervous System
- Eastern Europe
- Parent & Subsidiaries
- Selvita SA
- Senior Management
Pawel Przewiezlikowski , CEO
Boguslaw Sieczkowski , EVP, COO
Krzysztof Brzozka, PhD, EVP, CSO
Setareh Shamsili, MD, PhD, CMO
- Contact Info
Phone: 12 297 47 00
Park Life Science, Bobrzynskiego 14
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.